GTC Biotherapeutics has struck a deal to collaborate with France's LFB Biotechnologies on the development of recombinant plasma proteins and monoclonal antibodies using GTC's transgenics platform. As part of the deal, LFB will buy $25 million in GTC shares and convertible debt. Framingham, MA-based GTC recently obtained European approval of ATryn, a human blood clotting therapy that is produced in transgenic goat milk. It's the most advanced in a series of new transgenic therapies now in the pipeline. GTC is hoping to capitalize on its work in the field with a series of collaborations and seems to be well on its way to realizing its business plan.
- see the release on the discovery pact
EMEA panel recommends goat-milk therapy. Report
Pharming gets orphan status for transgenic therapy. Report